China Pharma Holdings (CPHI) Accounts Payables (2010 - 2026)

China Pharma Holdings (CPHI) has reported Accounts Payables for 17 consecutive years, with $2.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 11.57% year-over-year to $2.6 million; the trailing twelve-month figure through Jun 2026 stood at $2.6 million (up 11.57% YoY), and the FY2025 full-year result was $2.6 million, up 17.41% from the prior year.
• Accounts Payables grew to $2.6 million in Q2 2026 per CPHI's latest filing, from $2.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $2.6 million in Q2 2026 and bottomed at $1.6 million in Q2 2024.
• Historically, Accounts Payables has averaged $2.2 million across 5 years, with a median of $2.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables plunged 37.86% in 2022, then soared 45.92% in 2025.
• Over 5 years, Accounts Payables stood at $2.4 million in 2022, then dropped by 4.49% to $2.3 million in 2023, then fell by 4.37% to $2.2 million in 2024, then climbed by 17.41% to $2.6 million in 2025, then gained by 2.08% to $2.6 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $2.6 million, $2.6 million, and $2.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.